FDA Approves ARSENIC TRIOXIDE — Nexus Pharmaceuticals LLC

Nexus Pharmaceuticals LLC announced Thursday that it has received FDA approval for its generic version of Trisenox (arsenic trioxide) injection, marketed under ANDA #209780. This action enables the company to enter the market for an oncology treatment currently valued at hundreds of millions of dollars, effectively ending Nexus’ dependency on historical exclusivity privileges.